Stability engineering of the human antibody repertoire

FEBS Letters

Volumn 588, Issue 2, 2014, Pages 269-277

  Rouet, Romain ^a   Lowe, David ^b   Christ, Daniel ^a,c  

^a GARVAN INSTITUTE OF MEDICAL RESEARCH   (Australia)

^b MEDIMMUNE   (United States)

^c UNIVERSITY OF NEW SOUTH WALES   (Australia)

Author keywords

Antibody therapeutics; Protein aggregation; Protein engineering; Stability

Indexed keywords

CETUXIMAB; IMMUNOGLOBULIN G1 ANTIBODY; IMMUNOGLOBULIN G2A ANTIBODY; MONOCLONAL ANTIBODY;

ANTIBODY SPECIFICITY; BINDING AFFINITY; GENETIC RECOMBINATION; HUMAN; HYDROLYSIS; HYDROPHOBICITY; IMMUNOGENICITY; IONIC STRENGTH; MECHANICAL STRESS; PH MEASUREMENT; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN DENATURATION; PROTEIN DOMAIN; PROTEIN ENGINEERING; PROTEIN EXPRESSION; PROTEIN MOTIF; PROTEIN PURIFICATION; PROTEIN STABILITY; REVIEW; SEQUENCE HOMOLOGY; TEMPERATURE DEPENDENCE; THERMODYNAMICS; THERMOSTABILITY;

ANTIBODY THERAPEUTICS; PROTEIN AGGREGATION; PROTEIN ENGINEERING; STABILITY;

ANIMALS; ANTIBODIES, MONOCLONAL; HUMANS; PROTEIN ENGINEERING; PROTEIN MULTIMERIZATION; PROTEIN STABILITY; PROTEIN STRUCTURE, TERTIARY;

EID: 84892372545     PISSN: 00145793     EISSN: 18733468     Source Type: Journal    
DOI: 10.1016/j.febslet.2013.11.029     Document Type: Review

References (91)

1. A.L. Nelson, E. Dhimolea, and J.M. Reichert Development trends for human monoclonal antibody therapeutics Nat. Rev. Drug Discov. 9 2010 767 774
2. J.M. Finke, M. Roy, B.H. Zimm, and P.A. Jennings Aggregation events occur prior to stable intermediate formation during refolding of interleukin 1beta Biochemistry 39 2000 575 583
3. F. Baneyx, and M. Mujacic Recombinant protein folding and misfolding in Escherichia coli Nat. Biotechnol. 22 2004 1399 1408
4. S.E. Bondos, and A. Bicknell Detection and prevention of protein aggregation before, during, and after purification Anal. Biochem. 316 2003 223 231
5. D. Lowe, K. Dudgeon, R. Rouet, P. Schofield, L. Jermutus, and D. Christ Aggregation, stability, and formulation of human antibody therapeutics Adv. Protein Chem. Struct. Biol. 84 2011 41 61
6. S. Ewert, T. Huber, A. Honegger, and A. Pluckthun Biophysical properties of human antibody variable domains J. Mol. Biol. 325 2003 531 553
7. K. Dudgeon, R. Rouet, I. Kokmeijer, P. Schofield, J. Stolp, D. Langley, D. Stock, and D. Christ General strategy for the generation of human antibody variable domains with increased aggregation resistance Proc. Natl. Acad. Sci. USA 109 2012 10879 10884
8. E. Garber, and S.J. Demarest A broad range of Fab stabilities within a host of therapeutic IgGs Biochem. Biophys. Res. Commun. 355 2007 751 757
9. P.G. Wolynes, J.N. Onuchic, and D. Thirumalai Navigating the folding routes Science 267 1995 1619 1620
10. S. Sambashivan, Y. Liu, M.R. Sawaya, M. Gingery, and D. Eisenberg Amyloid-like fibrils of ribonuclease A with three-dimensional domain-swapped and native-like structure Nature 437 2005 266 269
11. C.M. Dobson Protein folding and misfolding Nature 426 2003 884 890
12. W. Wang Protein aggregation and its inhibition in biopharmaceutics Int. J. Pharm. 289 2005 1 30
13. A.S. Rosenberg Effects of protein aggregates: an immunologic perspective AAPS J. 8 2006 E501 E507
14. C.F. Wright, S.A. Teichmann, J. Clarke, and C.M. Dobson The importance of sequence diversity in the aggregation and evolution of proteins Nature 438 2005 878 881
15. S.J. Shire Formulation and manufacturability of biologics Curr. Opin. Biotechnol. 20 2009 708 714
16. J.G. Salfeld Isotype selection in antibody engineering Nat. Biotechnol. 25 2007 1369 1372
17. J. Schuurman, R. Van Ree, G.J. Perdok, H.R. Van Doorn, K.Y. Tan, and R.C. Aalberse Normal human immunoglobulin G4 is bispecific: it has two different antigen-combining sites Immunology 97 1999 693 698
18. A.F. Labrijn, J.I. Meesters, B.E. de Goeij, E.T. van den Bremer, J. Neijssen, M.D. van Kampen, K. Strumane, S. Verploegen, A. Kundu, M.J. Gramer, P.H. van Berkel, J.G. van de Winkel, J. Schuurman, and P.W. Parren Efficient generation of stable bispecific IgG1 by controlled Fab-arm exchange Proc. Natl. Acad. Sci. USA 110 2013 5145 5150
19. P.J. Carter Potent antibody therapeutics by design Nat. Rev. Immunol. 6 2006 343 357
20. H. Franey, S.R. Brych, C.G. Kolvenbach, and R.S. Rajan Increased aggregation propensity of IgG2 subclass over IgG1: role of conformational changes and covalent character in isolated aggregates Protein Sci. 19 2010 1601 1615
21. S.B. Hari, H. Lau, V.I. Razinkov, S. Chen, and R.F. Latypov Acid-induced aggregation of human monoclonal IgG1 and IgG2: molecular mechanism and the effect of solution composition Biochemistry 49 2010 9328 9338
22. T. Ito, and K. Tsumoto Effects of subclass change on the structural stability of chimeric, humanized, and human antibodies under thermal stress Protein Sci. 22 11 2013 1542 1551
23. J. Wypych, M. Li, A. Guo, Z. Zhang, T. Martinez, M.J. Allen, S. Fodor, D.N. Kelner, G.C. Flynn, Y.D. Liu, P.V. Bondarenko, M.S. Ricci, T.M. Dillon, and A. Balland Human IgG2 antibodies display disulfide-mediated structural isoforms J. Biol. Chem. 283 2008 16194 16205
24. E.R. Lacy, M. Baker, and M. Brigham-Burke Free sulfhydryl measurement as an indicator of antibody stability Anal. Biochem. 382 2008 66 68
25. S.J. Demarest, and S.M. Glaser Antibody therapeutics, antibody engineering, and the merits of protein stability Curr. Opin. Drug Discov. Devel. 11 2008 675 687
26. R. Gong, B.K. Vu, Y. Feng, D.A. Prieto, M.A. Dyba, J.D. Walsh, P. Prabakaran, T.D. Veenstra, S.G. Tarasov, R. Ishima, and D.S. Dimitrov Engineered human antibody constant domains with increased stability J. Biol. Chem. 284 2009 14203 14210
27. R.B. Pepinsky, L. Silvian, S.A. Berkowitz, G. Farrington, A. Lugovskoy, L. Walus, J. Eldredge, A. Capili, S. Mi, C. Graff, and E. Garber Improving the solubility of anti-LINGO-1 monoclonal antibody Li33 by isotype switching and targeted mutagenesis Protein Sci. 19 2010 954 966
28. X. Wang, T.K. Das, S.K. Singh, and S. Kumar Potential aggregation prone regions in biotherapeutics: a survey of commercial monoclonal antibodies MAbs 1 2009 254 267
29. H segments with different hypervariable loops J. Mol. Biol. 227 1992 776 798
30. L framework pairings with favorable biophysical properties MAbs 5 2013 445 470
31. L. Jespers, O. Schon, K. Famm, and G. Winter Aggregation-resistant domain antibodies selected on phage by heat denaturation Nat. Biotechnol. 22 2004 1161 1165
32. D. Christ, K. Famm, and G. Winter Repertoires of aggregation-resistant human antibody domains Protein Eng. Des. Sel. 20 2007 413 416
33. W. Wang, S. Singh, D.L. Zeng, K. King, and S. Nema Antibody structure, instability, and formulation J. Pharm. Sci. 96 2007 1 26
34. A. Lahlou, B. Blanchet, M. Carvalho, M. Paul, and A. Astier Mechanically-induced aggregation of the monoclonal antibody cetuximab Ann. Pharm. Fr. 67 2009 340 352
35. A.L. Daugherty, and R.J. Mrsny Formulation and delivery issues for monoclonal antibody therapeutics Adv. Drug Deliv. Rev. 58 2006 686 706
36. J. Buchner, and R. Rudolph Renaturation, purification and characterization of recombinant Fab-fragments produced in Escherichia coli Biotechnology (NY) 9 1991 157 162
37. C.M. Lee, H. McGuire, A. Basten, C. King, and D. Christ Expression, purification and characterization of recombinant interleukin-21 J. Immunol. Methods 362 2010 185 189
38. T. Arakawa, K. Tsumoto, Y. Kita, B. Chang, and D. Ejima Biotechnology applications of amino acids in protein purification and formulations Amino Acids 33 2007 587 605
39. H.C. Mahler, F. Senner, K. Maeder, and R. Mueller Surface activity of a monoclonal antibody J. Pharm. Sci. 98 2009 4525 4533
40. S.J. Demarest, J. Rogers, and G. Hansen Optimization of the antibody C(H)3 domain by residue frequency analysis of IgG sequences J. Mol. Biol. 335 2004 41 48
41. T. Teerinen, J. Valjakka, J. Rouvinen, and K. Takkinen Structure-based stability engineering of the mouse IgG1 Fab fragment by modifying constant domains J. Mol. Biol. 361 2006 687 697
42. G. Wozniak-Knopp, J. Stadlmann, and F. Ruker Stabilisation of the Fc fragment of human IgG1 by engineered intradomain disulfide bonds PLoS One 7 2012 e30083
43. H3 domain: generation, mechanisms of function, and implications for design of biological therapeutics J. Biol. Chem. 288 2013 25154 25164
44. H2 domains: increased stability and binding to the human neonatal Fc receptor J. Biol. Chem. 286 2011 27288 27293
45. S.J. Peters, C.M. Smales, A.J. Henry, P.E. Stephens, S. West, and D.P. Humphreys Engineering an improved IgG4 molecule with reduced disulfide bond heterogeneity and increased Fab domain thermal stability J. Biol. Chem. 287 2012 24525 24533
46. N. Chennamsetty, B. Helk, V. Voynov, V. Kayser, and B.L. Trout Aggregation-prone motifs in human immunoglobulin G J. Mol. Biol. 391 2009 404 413
47. N. Chennamsetty, V. Voynov, V. Kayser, B. Helk, and B.L. Trout Design of therapeutic proteins with enhanced stability Proc. Natl. Acad. Sci. USA 106 2009 11937 11942
48. J.V. Schaefer, and A. Pluckthun Engineering aggregation resistance in IgG by two independent mechanisms: lessons from comparison of Pichia pastoris and mammalian cell expression J. Mol. Biol. 417 2012 309 335
49. J.M. Perchiacca, A.R. Ladiwala, M. Bhattacharya, and P.M. Tessier Aggregation-resistant domain antibodies engineered with charged mutations near the edges of the complementarity-determining regions Protein Eng. Des. Sel. 25 2012 591 601
50. C. Hamers-Casterman, T. Atarhouch, S. Muyldermans, G. Robinson, C. Hamers, E.B. Songa, N. Bendahman, and R. Hamers Naturally occurring antibodies devoid of light chains Nature 363 1993 446 448
51. M. Arbabi Ghahroudi, A. Desmyter, L. Wyns, R. Hamers, and S. Muyldermans Selection and identification of single domain antibody fragments from camel heavy-chain antibodies FEBS Lett. 414 1997 521 526
52. HH antibody fragments and mouse monoclonal antibodies Biochim. Biophys. Acta 1431 1999 37 46
53. H domains J. Biol. Chem. 283 2008 3639 3654
54. L interface Biochemistry 41 2002 8570 8579
55. H domain from naturally occurring camel heavy chain immunoglobulins lacking light chains Protein Eng. 7 1994 1129 1135
56. S. Ewert, C. Cambillau, K. Conrath, and A. Pluckthun Biophysical properties of camelid V(HH) domains compared to those of human V(H)3 domains Biochemistry 41 2002 3628 3636
57. H domains FEBS Lett. 339 1994 285 290
58. J. Davies, and L. Riechmann Single antibody domains as small recognition units: design and in vitro antigen selection of camelized, human VH domains with improved protein stability Protein Eng. 9 1996 531 537
59. H domain J. Mol. Biol. 259 1996 957 969
60. J. Tanha, P. Xu, Z. Chen, F. Ni, H. Kaplan, S.A. Narang, and C.R. MacKenzie Optimal design features of camelized human single-domain antibody libraries J. Biol. Chem. 276 2001 24774 24780
61. K.H. Roux, A.S. Greenberg, L. Greene, L. Strelets, D. Avila, E.C. McKinney, and M.F. Flajnik Structural analysis of the nurse shark (new) antigen receptor (NAR): molecular convergence of NAR and unusual mammalian immunoglobulins Proc. Natl. Acad. Sci. USA 95 1998 11804 11809
62. A.S. Greenberg, D. Avila, M. Hughes, A. Hughes, E.C. McKinney, and M.F. Flajnik A new antigen receptor gene family that undergoes rearrangement and extensive somatic diversification in sharks Nature 374 1995 168 173
63. K. Griffiths, O. Dolezal, K. Parisi, J. Angerosa, C. Dogovski, M. Barraclough, A. Sanalla, J. Casey, I. González, M. Perugini, S. Nuttall, and M. Foley Shark variable new antigen receptor (VNAR) single domain antibody fragments: stability and diagnostic applications Antibodies 2 2013 66 81
64. P.T. Jones, P.H. Dear, J. Foote, M.S. Neuberger, and G. Winter Replacing the complementarity-determining regions in a human antibody with those from a mouse Nature 321 1986 522 525
65. S. Jung, and A. Pluckthun Improving in vivo folding and stability of a single-chain Fv antibody fragment by loop grafting Protein Eng. 10 1997 959 966
66. B. Steipe, B. Schiller, A. Pluckthun, and S. Steinbacher Sequence statistics reliably predict stabilizing mutations in a protein domain J. Mol. Biol. 240 1994 188 192
67. A. Kohl, H.K. Binz, P. Forrer, M.T. Stumpp, A. Pluckthun, and M.G. Grutter Designed to be stable: crystal structure of a consensus ankyrin repeat protein Proc. Natl. Acad. Sci. USA 100 2003 1700 1705
68. A. Worn, and A. Pluckthun Stability engineering of antibody single-chain Fv fragments J. Mol. Biol. 305 2001 989 1010
69. A. Knappik, L. Ge, A. Honegger, P. Pack, M. Fischer, G. Wellnhofer, A. Hoess, J. Wolle, A. Pluckthun, and B. Virnekas Fully synthetic human combinatorial antibody libraries (HuCAL) based on modular consensus frameworks and CDRs randomized with trinucleotides J. Mol. Biol. 296 2000 57 86
70. S. Ewert, A. Honegger, and A. Pluckthun Structure-based improvement of the biophysical properties of immunoglobulin VH domains with a generalizable approach Biochemistry 42 2003 1517 1528
71. J.V. Schaefer, and A. Pluckthun Transfer of engineered biophysical properties between different antibody formats and expression systems Protein Eng. Des. Sel. 25 2012 485 506
72. R.M. Murphy Peptide aggregation in neurodegenerative disease Annu. Rev. Biomed. Eng. 4 2002 155 174
73. B. Kuhlman, and D. Baker Native protein sequences are close to optimal for their structures Proc. Natl. Acad. Sci. USA 97 2000 10383 10388
74. A.M. Fernandez-Escamilla, F. Rousseau, J. Schymkowitz, and L. Serrano Prediction of sequence-dependent and mutational effects on the aggregation of peptides and proteins Nat. Biotechnol. 22 2004 1302 1306
75. A.P. Pawar, K.F. Dubay, J. Zurdo, F. Chiti, M. Vendruscolo, and C.M. Dobson Prediction of "aggregation-prone" and "aggregation- susceptible" regions in proteins associated with neurodegenerative diseases J. Mol. Biol. 350 2005 379 392
76. G.G. Tartaglia, A. Cavalli, R. Pellarin, and A. Caflisch Prediction of aggregation rate and aggregation-prone segments in polypeptide sequences Protein Sci. 14 2005 2723 2734
77. L. Jespers, O. Schon, L.C. James, D. Veprintsev, and G. Winter Crystal structure of HEL4, a soluble, refoldable human V(H) single domain with a germ-line scaffold J. Mol. Biol. 337 2004 893 903
78. P. Kristensen, and G. Winter Proteolytic selection for protein folding using filamentous bacteriophages Fold Des. 3 1998 321 328
79. P. Holliger, L. Riechmann, and R.L. Williams Crystal structure of the two N-terminal domains of g3p from filamentous phage fd at 1.9 Å: evidence for conformational lability J. Mol. Biol. 288 1999 649 657
80. L. Jermutus, A. Honegger, F. Schwesinger, J. Hanes, and A. Pluckthun Tailoring in vitro evolution for protein affinity or stability Proc. Natl. Acad. Sci. USA 98 2001 75 80
81. K. Dudgeon, R. Rouet, and D. Christ Rapid prediction of expression and refolding yields using phage display Protein Eng. Des. Sel. 26 10 2013 671 674
82. K. Famm, L. Hansen, D. Christ, and G. Winter Thermodynamically stable aggregation-resistant antibody domains through directed evolution J. Mol. Biol. 376 2008 926 931
83. M. Arbabi-Ghahroudi, R. To, N. Gaudette, T. Hirama, W. Ding, R. MacKenzie, and J. Tanha Aggregation-resistant VHs selected by in vitro evolution tend to have disulfide-bonded loops and acidic isoelectric points Protein Eng. Des. Sel. 22 2009 59 66
84. G. Hussack, T. Hirama, W. Ding, R. Mackenzie, and J. Tanha Engineered single-domain antibodies with high protease resistance and thermal stability PLoS One 6 2011 e28218
85. H domains Protein Eng. Des. Sel. 25 2012 581 589
86. H domains Protein Eng. Des. Sel. 22 2009 217 220
87. J.M. Perchiacca, M. Bhattacharya, and P.M. Tessier Mutational analysis of domain antibodies reveals aggregation hotspots within and near the complementarity determining regions Proteins 79 2011 2637 2647
88. C.C. Lee, J.M. Perchiacca, and P.M. Tessier Toward aggregation-resistant antibodies by design Trends Biotechnol. 31 11 2013 612 620
89. Christ, D. and Dudgeon, K. (2011) Modified variable domain molecules and methods for producing and using same. WO/2011/047442.
90. A. Buchanan, V. Clementel, R. Woods, N. Harn, M.A. Bowen, W. Mo, B. Popovic, S.M. Bishop, W. Dall'Acqua, R. Minter, L. Jermutus, and V. Bedian Engineering a therapeutic IgG molecule to address cysteinylation, aggregation and enhance thermal stability and expression MAbs 5 2013 255 262
91. C.M. Lee, N. Iorno, F. Sierro, and D. Christ Selection of human antibody fragments by phage display Nat. Protoc. 2 11 2007 3001 3008